KRAS and lung adenocarcinoma: Furthermore, KRAS mutation is a recently highlighted mutation,25 and KRAS inhibitor (AMG510) has shown antitumor activity in one case of partial response and two cases of stable disease among six patients with previously treated KRAS‐mutated lung adenocarcinoma.26